Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371078 | 0.78 | CCR1 (0.41) | MCHR1CCR1MEN1KMT2APOLB | |
| SCHEMBL24305728 | 0.74 | CCR1 (0.40) | CCR1RAB9ACCR5POLBTGFBR1 | |
| SCHEMBL17641054 | 0.72 | MCHR1 (0.68) | MCHR1CCR1RAB9ACCR5MEN1 | |
| SCHEMBL7519332 | 0.72 | CCR1 (0.46) | CCR1RAB9ACCR5KMT2APOLB | |
| SCHEMBL29812509 | 0.72 | MEN1 (0.40) | MEN1KMT2APOLBTGFBR1 | |
| SCHEMBL23147159 | 0.72 | MEN1 (0.40) | MEN1KMT2APOLBTGFBR1 | |
| SCHEMBL13738619 | 0.70 | CCR1 (0.50) | GRM5MCHR1CCR1RAB9ACCR5 | |
| SCHEMBL5264584 | 0.69 | TGFBR1 (0.45) | CCR1RAB9ACCR5MEN1KMT2A | |
| SCHEMBL3372322 | 0.69 | CCR1 (0.43) | CCR1RAB9ACCR5KMT2APOLB | |
| SCHEMBL30625762 | 0.69 | METAP2 (0.50) | CCR1RAB9ACCR5KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101155808-B | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | disclosed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| CN-101155808-A | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | CDK4, CDK1, CDK14 | GRM5 3627/4885MCHR1 3857/4885CCR1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.